As an innovative molecular cancer diagnostics company, Agendia uses its knowledge and expertise in the application of clinically useful gene expression profiling to facilitate diagnosis, prognosis and cancer therapeutics development.
Knowledge of a tumour’s gene expression profile can for example, be used to predict the ability of an individual’s tumour to metastasize and provide valuable insights into a tumour’s likely response to chemotherapy and targeted biologic therapies. In these examples, the information obtained is crucial to enable physicians to tailor the best course of therapy to each individual patient.
Agendia’s tests enable cancer researchers and pharmaceutical companies to differentiate between responders and non-responders when setting up clinical trials.
Agendia aims to develop a wide range of high-quality diagnostic methods using gene expression profiling based on microarray technologies and DNA mutation analysis to determine clinically relevant properties of tumours.